ChemPro Innovations
ChemPro Innovations is a leading biotechnology company at the forefront of chemical proteomics, leveraging innovative technologies for groundbreaking drug lead compound screening and target discovery within cellular environments. Our multidisciplinary approach spans chemical biology, bioinformatics, medicinal chemistry, and molecular and cellular biology, supported by a robust portfolio of core technology patents and state-of-the-art hardware platforms.
With established collaborations with pharmaceutical research enterprises and academic institutions, we are dedicated to rapidly overcoming barriers in identifying disease targets that remain elusive to traditional drug development approaches. Unlike conventional methods relying on purified proteins, our expertise lies in the revolutionary field of chemical proteomics, seamlessly transitioning drug discovery from purified proteins to live cellular systems.
Key Technological Platforms
1. Innovative Drug Lead Discovery in Unexplored Targets within Cells
2. Chemical Proteomics Analysis of Non-Covalent Drug-Target Interactions
3. Differential Proteomics Analysis Facilitating Target Discovery
4. Chemical Proteomics Analysis of Covalent Drug-Target Interactions
5. Discovery of Non-Covalent Drug Docking within Cellular Environments
6. PROTAC Protein Target and Degradation Profile Analysis
Our Chemical Proteomics Screening Platform enables the discovery of novel binding pockets and ligands for endogenous target proteins within live cells, covering a vast array of over 10,000 proteins and 40,000 binding sites. Identifies biologically active molecules in disease-relevant cells or tissues, widely applied in drug target discovery, novel mechanism research, and off-target protein analysis.
Grounded in the forefront of chemical biology, with a commitment to focused innovation, ChemPro Innovations aims to drive the industrial application of chemical proteomics technology in the field of new drug development. We invite you to explore the possibilities of collaboration and innovation as we continue to push the boundaries of discovery.
